Celldex Therapeutics (CLDX) Current Assets (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Current Assets of $459.2 million for Q1 2026, down 33.81% year-over-year from $693.8 million in Q1 2025, and down 14.11% quarter-over-quarter from $534.7 million in Q4 2025.
Celldex Therapeutics (CLDX) Current Assets (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $459.2 million for Q1 2026.
- In Q1 2026, Current Assets fell 33.81% year-over-year to $459.2 million; the TTM figure through Mar 2026 stood at $459.2 million (down 33.81% YoY), while the FY2025 annual figure was $534.7 million, down 28.44% from the prior year.
- Current Assets for Q1 2026 stood at $459.2 million, down from $534.7 million in the prior quarter.
- The five-year high for Current Assets was $835.3 million in Q1 2024, with the low at $245.9 million in Q3 2023.
- The 5-year median for Current Assets is $459.2 million (2026), against an average of $515.1 million.
- The sharpest annual moves came in 2024 and 2026: Current Assets soared 216.69% in 2024, then slumped 33.81% in 2026.
- Celldex Therapeutics' Current Assets stood at $317.7 million in 2022, then soared by 35.88% to $431.7 million in 2023, then surged by 73.08% to $747.2 million in 2024, then slipped by 28.44% to $534.7 million in 2025, then fell by 14.11% to $459.2 million in 2026.
- Business Quant data shows CLDX's Current Assets at $459.2 million in Q1 2026, $534.7 million in Q4 2025, and $604.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 724.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 724.93 Mn |
| Mar 31, 2026 | 459.22 Mn |
| Dec 31, 2025 | 534.66 Mn |
| Sep 30, 2025 | 604.34 Mn |
| Jun 30, 2025 | 648.40 Mn |
| Mar 31, 2025 | 693.76 Mn |
| Dec 31, 2024 | 747.16 Mn |
| Sep 30, 2024 | 778.84 Mn |
| Jun 30, 2024 | 811.98 Mn |
| Mar 31, 2024 | 835.32 Mn |
| Dec 31, 2023 | 431.69 Mn |
| Sep 30, 2023 | 245.93 Mn |
| Jun 30, 2023 | 264.82 Mn |
| Mar 31, 2023 | 289.60 Mn |
| Dec 31, 2022 | 317.69 Mn |
| Sep 30, 2022 | 334.60 Mn |
| Jun 30, 2022 | 367.98 Mn |
| Mar 31, 2022 | 390.70 Mn |
| Dec 31, 2021 | 410.84 Mn |
| Sep 30, 2021 | 426.56 Mn |